Copertina

Comparative analysis of real‐world acute prescription migraine therapy outcomes: Insights from the HeAD – US study

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Devin Teichrow, Babak Khorsand, Kristina M. Fanning, Alexandre Urani, François Cadiou, Richard B. Lipton, Ali Ezzati
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2026
Soggetti:	Headache: The Journal of Head and Face Pain
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Real‐world barriers to health care utilization among people living with migraine: Insights from the All of Us Research Program
di: Idris Demirsoy, et al.
Pubblicazione: (2025)

Rates and healthcare resource utilization for people with branded acute and preventive migraine prescription medication order payer denials: An open, multi‐source dataset, observational cohort study
di: Dawn C. Buse, et al.
Pubblicazione: (2026)

Ubrogepant users' real‐world experience: Patients on ubrogepant, characteristics and outcomes (UNIVERSE) study
di: Anand R. Shewale, et al.
Pubblicazione: (2024)

Prevalence and burden of migraine in the United States: A systematic review
di: Fred Cohen, et al.
Pubblicazione: (2024)

Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi‐country results from the CaMEO‐I study
di: Dawn C. Buse, et al.
Pubblicazione: (2024)

Integrating gepants into clinical practice for the acute treatment of migraine
di: Richard B. Lipton, et al.
Pubblicazione: (2026)

What a long strange trip it's been: Reflections on serial snapshots of migraine prevalence and burden in the United States
di: Fred Cohen, et al.
Pubblicazione: (2025)

Challenges and opportunities for estimating and assessing migraine prevalence, incidence and impact across study populations and methodologies: Bridging global and United States findings
di: Fred Cohen, et al.
Pubblicazione: (2024)

Unmet treatment needs in migraine: Results of the OVERCOME (US) study
di: Susan Hutchinson, et al.
Pubblicazione: (2026)

Reasons for patient reluctance to take preventive medications for migraine: Results of the OVERCOME ( US ) study
di: Jessica Ailani, et al.
Pubblicazione: (2026)

Patient reported outcomes and the real‐world use of calcitonin gene–related peptide medications in migraine
di: Samuel K. Peasah, et al.
Pubblicazione: (2024)

Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study
di: Dawn C. Buse, et al.
Pubblicazione: (2025)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
di: Rikki Mangrum, et al.
Pubblicazione: (2024)

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
di: David Kudrow, et al.
Pubblicazione: (2025)

Depression and anxiety are not associated with migraine outcomes in children and adolescents
di: Amy A. Gelfand
Pubblicazione: (2024)

Patient preferences for the preventive treatment of episodic migraine in the United States: A discrete‐choice experiment
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Anxiety and depressive symptoms and migraine‐related outcomes in children and adolescents
di: Bilal Ahmed Rizvi, et al.
Pubblicazione: (2024)

The impact of headache intensity on speech in participants with migraine and acute post‐traumatic headache
di: Dani C. Smith, et al.
Pubblicazione: (2024)

Characterizing the patient experience during the prodrome phase of migraine: A qualitative study of symptoms and their timing
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Novel optimization of multi‐mechanistic approaches for the acute treatment of a migraine attack: A review
di: Stephen Silberstein, et al.
Pubblicazione: (2026)

Navigating the patient journey in migraine prevention: An American Migraine Foundation position paper
di: Lawrence C. Newman, et al.
Pubblicazione: (2025)

A 3‐year follow‐up study of outcomes associated with patterns of traditional acute and preventive migraine treatment: An administrative claims‐based cohort study in the United States
di: Shivang Joshi, et al.
Pubblicazione: (2024)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
di: Anna Gryglas‐Dworak, et al.
Pubblicazione: (2024)

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
di: Stephen D. Silberstein, et al.
Pubblicazione: (2024)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
di: Richard B. Lipton, et al.
Pubblicazione: (2025)

Do patients with migraine and obesity receive different treatments? Insights from real‐world data
di: Keshet Pardo, et al.
Pubblicazione: (2025)

Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial
di: Ghader Mohammadnezhad, et al.
Pubblicazione: (2024)

Effectiveness of switching strategies in CGRP monoclonal antibody therapy for migraine: A retrospective cohort study
di: Alex Jaimes, et al.
Pubblicazione: (2024)

Rising migraine incidence in adolescents despite stable prevalence in the US : A call for further investigation
di: Ali Reza Tavasoli, et al.
Pubblicazione: (2024)

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
di: Nathaniel M. Schuster, et al.
Pubblicazione: (2025)

Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon
di: Stephanie J. Nahas, et al.
Pubblicazione: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
di: Graham A. McLeod, et al.
Pubblicazione: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
di: Koichi Ikeda, et al.
Pubblicazione: (2025)

Combination behavioral and pharmacological interventions through telehealth platforms: Opportunities for increasing access and optimizing migraine outcomes
di: Teshamae S. Monteith, et al.
Pubblicazione: (2025)

Routine migraine screening as a standard of care for Women's health: A position statement from the American Headache Society
di: Todd J. Schwedt, et al.
Pubblicazione: (2025)

2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
di: Jennifer Robblee, et al.
Pubblicazione: (2025)

Exploring the impact of acute SARS‐CoV‐2 infection on headache pattern in patients with migraine: A novel Bayesian analysis
di: Jiunn‐Tyng Yeh, et al.
Pubblicazione: (2025)

The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
di: Jennifer Robblee, et al.
Pubblicazione: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
di: Yunus Emre Meydanal, et al.
Pubblicazione: (2025)

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open‐label ASCEND acute migraine study
di: Jessica Ailani, et al.
Pubblicazione: (2025)